{
    "RADCURE-3833": {
        "recruit-recruiter": "1. Radiation Oncologist - Your expertise is strictly limited to radiation therapy planning and dosing for head and neck squamous cell carcinoma, especially HPV-negative cases involving the larynx supraglottis subsite. - Hierarchy: Radiation Oncologist",
        "question": "Age: 58.4, Sex: Male, ECOG PS: ECOG 1, Smoking PY: 30, Smoking Status: Current, Ds Site: Larynx, Subsite: Supraglottis, T: T4a, N: N0, M : M0, Stage: IVA, Path: Squamous Cell Carcinoma, HPV: none, Tx Modality: RT alone, Chemo? : none, Dose: 64.0, Fx: 40, Local: Yes, Regional: none, Distant: Yes, 2nd Ca: none, ContrastEnhanced: 0\nAnswer: ",
        "think-initial_assessment-radiation oncologist": "<think> Okay, let's see. The patient is a 58-year-old male with a supraglottic squamous cell carcinoma of the larynx, staged T4a N0 M0, which is Stage IVA. He's HPV-negative, a current smoker with a 30 pack-year history. He received radiation therapy alone at a dose of 64 Gy in 40 fractions. The treatment outcomes include local and distant recurrence, but no regional recurrence.\n\nFirst, HPV-negative status is a negative prognostic factor in head and neck cancers, especially oropharyngeal, but here it's laryngeal. However, HPV is less commonly implicated in laryngeal cancers, so maybe the impact here is less clear. Still, smoking is a significant risk factor and can contribute to worse outcomes.\n\nT4a indicates a locally advanced tumor, invading through the thyroid cartilage and/or invading tissues beyond the larynx, like the trachea or soft tissues of the neck. N0 suggests no nodal involvement, which is a bit better, but T4a still makes it high risk.\n\nHe received RT alone without chemo. Current standard for locally advanced laryngeal cancer often involves concurrent chemoradiation, especially for organ preservation. However, this patient didn't get chemo. The dose is 64 Gy in 40 fractions, which is a standard fractionation (2 Gy per fraction equivalent). But maybe for definitive treatment, higher doses (e.g., 70 Gy) are more typical. Wait, 64 Gy in 40 fractions would be 1.6 Gy per fraction if given daily, but that's unusual. Wait, maybe it's 2 Gy per fraction over 32 fractions (which would be 64 Gy total). Wait, 40 fractions at 64 Gy would be 1.6 Gy per fraction. Hmm, that might be a hypofractionated regimen or split course? Not sure. Alternatively, maybe it's 2 Gy x 32 fractions (64 Gy/32 fx), but 32 fractions would be about 6.5 weeks. Wait, 40 fractions of 1.6 Gy each is 64 Gy over 8 weeks (assuming 5 fractions per week). That seems like a conventional fractionation but with lower per-fraction doses. Maybe it's a different protocol, but I'm not sure. Alternatively, maybe the dose is 64 Gy in 40 fractions, which would be 1.6 Gy per fraction twice a day? But that's more common for accelerated or hyperfractionated regimens. Wait, 40 fractions of 1.6 Gy once daily would take 8 weeks. But standard is usually around 70 Gy in 35 fractions over 7 weeks. So 64 Gy is lower than typical. Maybe this was a palliative approach? But the patient had local and distant recurrence. If the dose was lower, maybe the treatment was not curative intent, but the staging is IVA, which is still potentially curable. Alternatively, maybe the patient couldn't tolerate higher doses. But the fact that there's local recurrence suggests that the radiation was not effective in controlling the primary tumor. Distant recurrence also indicates systemic spread, which is a poor prognostic sign.\n\nSmoking history and continued smoking can contribute to poorer treatment response and higher rates of recurrence. The presence of both local and distant recurrence would significantly impact survival. Patients with distant metastases in head and neck cancer generally have a poor prognosis, with median survival often less than a year. Even with salvage therapy, outcomes are typically poor.\n\nConsidering all these factors: HPV-negative, current smoker, T4a disease, treatment with RT alone at a dose that might be lower than standard, and development of both local and distant recurrence. The patient's survival probability is likely poor. The presence of distant metastasis is a key determinant here. So the answer would be Dead.",
        "initial_assessment-radiation oncologist": "Answer: Dead",
        "Round 1-role-comment": "radiation oncologist:dead",
        "Round 1-num_agents": 1,
        "think-Round 2-Turn 1-discuss-participate-radiation oncologist": "<think> Okay, let me start by going through the case details again. The patient is a 58-year-old male with a current smoking history of 30 pack-years. He has a supraglottic squamous cell carcinoma of the larynx, staged as T4a N0 M0 IVA, and HPV-negative. The treatment given was radiation therapy alone with a dose of 64 Gy in 40 fractions. The outcomes include both local and distant recurrence, with no second primary cancers noted.\n\nFrom a radiation oncology perspective, HPV-negative head and neck cancers, especially in smokers, tend to have a worse prognosis compared to HPV-positive ones. The T4a classification indicates a locally advanced tumor, which is associated with lower control rates. Even though it's N0, the presence of distant metastasis (distant recurrence) significantly impacts survival. The use of RT alone without concurrent chemotherapy might be a factor here, as concurrent chemoradiation is often standard for locally advanced cases to improve outcomes. However, this patient didn't receive chemo, possibly due to contraindications or patient choice. The dose of 64 Gy is within conventional ranges, but local recurrence suggests possible radioresistance or inadequate coverage. Considering all these factors—advanced stage, smoking, HPV-negative status, distant recurrence—the consensus among the radiation oncologist's team points towards a poor prognosis, hence the answer 'Dead'. Since the team's opinion is already unified and no conflicting viewpoints are presented, consulting additional experts isn't necessary here.",
        "Round 2-Turn 1-discuss-participate-radiation oncologist": "no  \nAnswer: Dead",
        "think-Round 2-Turn 1-ask_gap-radiation oncologist": "<think> Okay, let me think through this. The user is a radiation oncologist focused on head and neck squamous cell carcinoma, especially HPV-related cases. The current team includes only a radiation oncologist. The patient has a laryngeal squamous cell carcinoma, T4a, N0, M0, Stage IVA, treated with RT alone at 64 Gy in 40 fractions. The outcome was Dead.\n\nFirst, the existing team has only a radiation oncologist. The patient's case includes factors like current smoking status, advanced T stage, and treatment with RT alone without chemo. The question is whether additional specialists are needed beyond the existing team. \n\nThe guidelines say not to suggest experts already in the team. Since the current team is only a radiation oncologist, other specialties might be needed. For example, an ENT surgeon could provide insight into surgical options or resectability. A medical oncologist could discuss systemic therapy options, especially since chemo wasn't used here. A pathologist might confirm HPV status (though HPV is negative here). However, since the user's expertise is strictly radiation planning and dosing, and the question is about survival probability, perhaps the existing input is sufficient. But considering treatment decisions (like why chemo wasn't given), a medical oncologist's input could address that gap. But the user's role is to collaborate, so maybe they need to consult others. However, the user's answer was Dead, implying they might have considered all factors. Wait, the original question was about survival probability based on the given factors. The radiation oncologist's opinion is Dead. But maybe other factors like recurrence sites (Local and Distant) could involve medical oncology for systemic treatment or palliative care. However, the task is to decide if any additional specialist is needed beyond the existing team (radiation oncologist). Since the current team only has a radiation oncologist, and the case involves treatment modality (RT alone without chemo), which is a medical oncology decision, adding a medical oncologist could be necessary. Therefore, the answer would be yes because the team lacks a medical oncologist to address the systemic therapy aspect, which impacts survival.",
        "Round 2-Turn 1-ask_gap-radiation oncologist": "---\nAnswer: yes  \nReason: systemic therapy consideration  \n---",
        "Round 2-Turn 1-gap_identified-assistant": "Recommendation: Consult a medical oncologist for systemic therapy consideration.",
        "Round 2-Turn 1-gap_recruit-recruiter": "1. Medical Oncologist - Your expertise is strictly limited to systemic therapy decisions, including chemotherapy and immunotherapy in head and neck cancers. - Hierarchy: Medical Oncologist == Radiation Oncologist",
        "think-Round 2-Turn 1-gap_recruited_assessment-medical oncologist": "<think> Okay, let's tackle this case step by step. The patient is a 58-year-old male with a history of current smoking (30 pack-years) and has been diagnosed with T4aN0M0 stage IVA squamous cell carcinoma of the supraglottic larynx, HPV-negative. The treatment he received was radiation therapy alone (64 Gy in 40 fractions), without any chemotherapy or immunotherapy. The outcomes show both local and distant recurrence.\n\nFirst, considering the stage and characteristics. T4a indicates a large tumor invading adjacent structures like thyroid cartilage or beyond. N0 means no lymph node involvement, but M0 suggests no distant metastasis at diagnosis. However, the presence of both local and distant recurrence now complicates the picture. HPV-negative status is a negative prognostic factor in head and neck cancers, associated with worse outcomes compared to HPV-positive cases.\n\nThe patient received RT alone. For locally advanced head and neck squamous cell carcinoma (HNSCC), the standard of care typically involves concurrent chemoradiation, especially in high-risk patients. The omission of chemotherapy here might be due to patient factors like comorbidities or refusal, but in this case, the ECOG PS is 1, which is generally acceptable for chemotherapy. Without systemic therapy, the risk of both local and distant failure increases. \n\nSmoking is another poor prognostic factor, contributing to lower response rates and higher chances of recurrence. The development of distant metastasis post-treatment indicates systemic spread, which is a major determinant of survival. Once distant metastasis occurs, the prognosis is generally poor, with median survival often less than a year even with palliative chemotherapy or immunotherapy. \n\nIn this scenario, the patient has already failed initial RT with both local and distant progression. As a medical oncologist, the next steps might involve considering systemic therapy options like platinum-based chemotherapy, immunotherapy (e.g., pembrolizumab or nivolumab), or targeted therapies. However, the presence of distant metastasis significantly reduces survival rates. Even with systemic treatment, the response rates are modest, and survival beyond a year is not common, especially in HPV-negative, heavy smokers.\n\nAdditionally, the patient's current smoking status might impair treatment efficacy and overall health, further worsening prognosis. The combination of aggressive tumor biology (HPV-negative), advanced initial stage, recurrence both locally and distantly, and lack of prior systemic therapy all point towards a very poor prognosis. Therefore, despite potential systemic treatments, the likelihood of survival at this point is very low.",
        "Round 2-Turn 1-gap_recruited_assessment-medical oncologist": "Answer:Dead",
        "think-Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-medical oncologist": "<think> Okay, so I need to figure out whether I should consult another expert based on the existing opinions. The previous opinions were both 'dead', meaning the other experts, like the radiation oncologist, have already weighed in and agree on the outcome.\n\nAs a medical oncologist, my focus is on systemic therapies. The patient had T4a laryngeal squamous cell carcinoma, stage IVA, HPV-negative, and was treated with RT alone without chemotherapy. The recurrence includes both local and distant metastases. Given that he's a current smoker with a 30 pack-year history, his prognosis is already poor. HPV-negative status is another negative prognostic factor. The use of RT alone without concurrent chemo might have contributed to treatment failure, as concurrent chemoradiation is standard for locally advanced cases. \n\nSince distant metastasis occurred, systemic therapy like immunotherapy (e.g., pembrolizumab) or chemotherapy might be considered for palliation, but the question is about survival probability. The existing opinions from the team are unanimous. Since my role is systemic therapy and the team already agrees, there's no need for another expert. I concur with 'dead' based on the factors mentioned. No additional expertise seems necessary here.",
        "Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-medical oncologist": "Answer:Dead",
        "Round 2-role-comment": "radiation oncologist:dead|medical oncologist:dead",
        "Round 2-num_agents": 2,
        "num_cooperations-panel": 0,
        "decision-Moderator": "('Answer: Dead',)\n(radiation oncologist): Answer: Dead\n(medical oncologist): Answer: Dead"
    }
}